Aurinia Pharmaceuticals Inc.
AUPH
$12.27
$0.191.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.59% | 29.20% | 33.97% | 38.72% | 29.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.59% | 29.20% | 33.97% | 38.72% | 29.35% |
| Cost of Revenue | -17.15% | -21.20% | -23.13% | -14.14% | 18.77% |
| Gross Profit | 43.98% | 54.23% | 66.57% | 70.29% | 34.50% |
| SG&A Expenses | -33.97% | -24.89% | -11.80% | -3.83% | -3.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1,299.07% | 622.06% | -37.35% | 216.34% | 124.12% |
| Total Operating Expenses | -22.49% | -19.42% | -14.81% | -3.84% | 4.39% |
| Operating Income | 234.13% | 167.65% | 114.59% | 78.88% | 43.56% |
| Income Before Tax | 229.91% | 167.75% | 109.61% | 73.58% | 32.38% |
| Income Tax Expenses | -17.90% | 129.74% | 207.80% | 154.59% | 40.49% |
| Earnings from Continuing Operations | 220.43% | 163.69% | 107.37% | 70.78% | 30.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 220.43% | 163.69% | 107.37% | 70.78% | 30.78% |
| EBIT | 234.13% | 167.65% | 114.59% | 78.88% | 43.56% |
| EBITDA | 404.20% | 231.75% | 143.11% | 100.59% | 66.31% |
| EPS Basic | 224.51% | 164.82% | 107.47% | 70.97% | 31.19% |
| Normalized Basic EPS | 302.44% | 210.10% | 139.53% | 83.82% | 43.55% |
| EPS Diluted | 222.15% | 162.92% | 107.41% | 70.91% | 31.19% |
| Normalized Diluted EPS | 297.16% | 207.07% | 138.38% | 83.46% | 43.55% |
| Average Basic Shares Outstanding | -2.46% | -0.89% | 0.24% | 0.55% | 0.69% |
| Average Diluted Shares Outstanding | 0.03% | 1.41% | 1.80% | 1.14% | 0.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |